Wednesday, October 8, 2025

Latest

Medicago, GSK Report 71% Efficacy Rate From Plant-Based COVID-19 Vaccine Study

Quebec-based biopharmaceutical firm Medicago and healthcare conglomerate GlaxoSmithKline (NYSE: GSK) announce today the results from its global Phase 3 efficacy study of its COVID-19 vaccine candidate. The data showed an overall efficacy rate of 71% against all variants of SARS-CoV-2, the virus that causes the pandemic disease.

The Canadian firm’s plant-based vaccine candidate is combined with GSK’s pandemic adjuvant. The firm is using a unique technology to produce virus-like particles, designed to mimic the virus structure for the immune system to recognize ahead of the potential infection.

The study, started in March 2021, was conducted with over 24,000 subjects ages 18 years old and above across Canada, the United States, the United Kingdom, Mexico, Argentina, and Brazil. The vaccine was administered in two doses of 3.75 µg, 21 days apart.

The vaccine candidate also showed a 75.3% efficacy rate specifically against the Delta variant and 88.6% against the Gamma variant. The emerging Omicron variant has not been considered yet in the study.

During the study, the firm reported no related serious adverse events while reactions to the vaccine were “generally mild to moderate and transient”, with “symptoms lasting on average only 1 to 3 days.”

The biopharmaceutical firm plans to seek regulatory approval from Health Canada as part of its rolling submission. The phase 3 results are also expected to be released in a peer-reviewed publication.


Information for this briefing was found via the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Sona Nanotech Announces $2.0 Million Private Placement

Sona Nanotech (CSE: SONA) this morning announced that it is looking to raise funds via...

Thursday, December 3, 2020, 09:27:21 AM

Sona Nanotech Approved For Clinical Trials of Saliva-Based COVID-19 Rapid Test

Sona Nanotech (CSE: SONA) has been approved to begin clinical trials. The company this morning...

Tuesday, April 13, 2021, 08:21:40 AM

Relay Medical Joint Venture Sees COVID-19 Device Launched In Rural Texas Hospitals

Relay Medical Corp (CSE: RELA) this morning announced that its joint venture with Fio Corp,...

Monday, November 23, 2020, 08:15:11 AM

Sona Nanotech Withdraws Health Canada Application For COVID-19 Test Due To Feedback From Regulator

In what is a major blow to shareholders of Sona Nanotech (CSE: SONA), the company...

Wednesday, November 25, 2020, 02:31:06 PM

#PfizerExposed: Did Pfizer Just Admit To “Engineering” Virus For COVID-19 Pill In Response To Project Veritas Video?

After a video of a top Pfizer (NYSE: PFE) executive relaying that the biotech firm...

Saturday, January 28, 2023, 10:59:30 AM